Peer Exchange
June 29, 2018 –
Shawn Davis, PharmD, defines hyperhidrosis and remarks on current limitations in recognizing it as a clinical condition.
June 29, 2018 –
Dee Anna Glaser, MD; Adelaide Hebert, MD; and Adam Friedman, MD, FAAD, outline the signs and symptoms of hyperhidrosis and differentiate between the primary focal and secondary generalized types.
April 02, 2018 –
Michael G. Sension, MD; Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; and Elly Fatehi, PharmD, MPH, offer their perspectives on the challenges with determining the cost effectiveness of newer HIV therapies versus existing therapies.
March 26, 2018 –
Peter L. Salgo, MD; Michael G. Sension, MD; Jeffrey D. Dunn, PharmD, MBA; and Elly Fatehi, PharmD, MPH, discuss emerging therapies in HIV and the impact that effective therapies have had on sense of urgency.
March 26, 2018 –
Peter L. Salgo, MD; Michael G. Sension, MD; Elly Fatehi, PharmD, MPH; and Jeffrey D. Dunn, PharmD, MBA, examine the potential for collaboration among payers and providers to achieve good clinical outcomes in HIV treatment that are cost effective.
March 19, 2018 –
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, offer insight regarding the potential impact that tighter management of HIV agents would have on clinical decision making.
March 19, 2018 –
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, discuss the challenges with payer management of HIV therapies.
March 12, 2018 –
Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Michael G. Sension, MD; and Elly Fatehi, PharmD, MPH, discuss the difficulty in finding a common ground with clinical decision making and cost control for HIV therapies.
March 12, 2018 –
Peter L. Salgo, MD; Elly Fatehi, PharmD, MPH; Jeffrey D. Dunn, PharmD, MBA; and Michael G. Sension, MD, discuss the connection between poor compliance and development of resistance in patients with HIV.
March 05, 2018 –
Peter L. Salgo, MD; Elly Fatehi, PharmD, BCPS; Michael Sension, MD; and Jeffrey Dunn, PharmD, explore scenarios that require HIV treatments that fall outside of the guideline recommendations for most patients.
